Semaxanib

Generic Name: Semaxanib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O

CAS Number: 194413-58-6

Unique Ingredient Identifier: 71IA9S35AJ

Indication: Investigated for use/treatment in colorectal cancer and lung cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: semaxanib
Drug: thalidomide

First Posted Date: 2003-06-12

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00017316

Locations: 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

Phase 2

Completed

Conditions: Carcinoma of Unknown Primary
Head and Neck Cancer
Non-melanomatous Skin Cancer

First Posted Date: 2003-05-30

Last Posted Date: 2009-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00006361

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-05-23

Last Posted Date: 2018-06-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00004868

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Neuro-Oncology Branch, Bethesda, Maryland, United States

and more 9 locations

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage III Colon Cancer
Stage III Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: semaxanib
Other: laboratory biomarker analysis

First Posted Date: 2003-05-05

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 68

Registration Number: NCT00005818

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

Phase 2

Terminated

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: semaxanib
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00006003

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT00005822

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio, United States

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Phase 1

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT00005647

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy